Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018799 (heart disease)
 34,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

To evaluate the attenuation of the effectiveness of long-term ibopamine therapy, ibopamine was administered in single doses of 100 and 200 mg to 10 patients with chronic heart disease. The hemodynamic studies using Swan-Ganz catheter and pharmacokinetic studies were carried out. Ibopamine was found to increase cardiac output and stroke index and to decrease systemic vascular resistance in this acute study. Six patients underwent long-term therapy with the drug and were evaluated for the development of tolerance. Three out of 5 patients experienced an improvement in NYHA functional class after 12-23 weeks of treatment. There was no attenuation in the effects of ibopamine on hemodynamics, pharmacokinetic parameters remained almost unchanged, and tolerance was not observed. These results suggest that ibopamine is useful as an orally administered anti-heart failure drug.
 ...
PMID:Hemodynamic effects and pharmacokinetics of long-term therapy with ibopamine in patients with chronic heart failure. 145 Nov 23

The acute hemodynamic effects of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine which can be administered orally, were compared with those of dopamine. Ten male patients aged 54 years on average, with chronic congestive heart failure in NYHA (New York Heart Association) classes II-IV were studied. Eight of them were suffering from idiopathic congestive cardiomyopathy and two from ischemic cardiopathy. Baseline hemodynamic parameters were recorded within 24 h after withdrawal of previous treatment, the patients being kept on digitalis only. The investigation was carried out for a period of 3 days running. On day 1 of treatment one group of 5 patients were given dopamine at increasing doses of 2, 4 and 6 micrograms/kg/min. Their hemodynamic parameters were assessed 15 min after each dose and 15 and 60 min after withdrawal of the drug. Ibopamine was then administered orally in single doses of 50 mg on day 2 and 100 mg on day 3. The hemodynamic parameters were evaluated at 30, 60, 90, 120, 180, 360 and 480 min after administration. On day 1, another group of 5 patients were given 50 mg ibopamine, on day 2, 100 mg ibopamine and on day 3, dopamine. Hemodynamic data in this group of patients were evaluated at the same times mentioned above. The hemodynamic effects of ibopamine 100 mg are very similar to those obtained with 4 micrograms/kg/min dopamine. Indeed, the effects of both drugs on the cardiac index, right atrial pressure, peripheral and pulmonary vascular resistance do not differ significantly from each other.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Comparison of the acute hemodynamic effects of ibopamine and dopamine in chronic congestive heart failure. 370 49